Dendris Overview

  • Status
  • Private

  • Latest Deal Type
  • Angel

  • Latest Deal Amount
  • $856K

  • Investors
  • 2

Dendris General Information

Description

Developer of a biotechnological chip designed to perform syndromic diagnosis of infectious bacteria. The company's chip performs a syndromic test allowing to the analysis of bacteria simultaneously based on the functionalization of the support by phosphorus dendrimers, enabling clinicians to diagnose causes of illness in a reliable and cost-effective manner.

Contact Information

Website
www.dendris.fr
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Corporate Office
  • 335 rue du chene vert
  • 31670 Labege
  • France
+33 05 00 00 00 00

Dendris Timeline

2021202220232024
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dendris Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Angel (individual) 06-Dec-2022 $856K 00.000 00.000 Completed Generating Revenue
6. Angel (individual) 30-Jun-2021 00.000 00.000 00.000 Completed Generating Revenue
5. Angel (individual) 02-May-2019 00000 00.000 00.000 Completed Generating Revenue
4. Angel (individual) 25-Jan-2018 00000 00.000 00.000 Completed Generating Revenue
3. Angel (individual) 29-Apr-2016 00000 00.000 00.000 Completed Generating Revenue
2. Angel (individual) 01-Jun-2015 $678K $678K 00.000 Completed Generating Revenue
1. Accelerator/Incubator 07-Mar-2008 Completed Generating Revenue
To view Dendris’s complete valuation and funding history, request access »

Dendris Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B Shares 0,000 000.000000 0000.00 0000.00 00 0000.00 0.000
A Shares 000 000.000000 0000.00 0000.00 00 0000.00 0.000
B Shares 0,000 000.000000 0000.00 0000.00 00 0000.00 00.00
A Shares 0,000 000.000000 0000.00 0000.00 00 0000.00 0.00
Ordinary Shares 0,000 000.000000 0000.0 0000.0 00 0000.0 00.000
Ordinary Shares 2,399 $10.308272 $206.17 $206.17 1x $206.17 11%
Ordinary Shares 6,525 $10.308272 $172.15 $172.15 1x $172.15 29.92%
To view Dendris’s complete cap table history, request access »

Dendris Patents

Dendris Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3028046-B1 Method of immobilizing a compound of interest on a support according to a designed pattern and kit for its implementation Inactive 29-Oct-2014 00000000000
US-20180311635-A1 Method for immobilising a compound of interest on a substrate in a given pattern and kit for implementing same Inactive 29-Oct-2014 00000000000
FR-3028046-A1 Method of immobilizing a compound of interest on a support according to a designed pattern and kit for its implementation Active 29-Oct-2014 00000000000
CA-3000291-A1 Method for immobilising a compound of interest on a substrate in a given pattern and kit for implementing same Inactive 29-Oct-2014 00000000000
FR-2995614-B1 Biopuce for the detection and / or identification of bacteria of the genus legionella, kit and method of use Inactive 19-Sep-2012 C12Q1/689
To view Dendris’s complete patent history, request access »

Dendris Executive Team (5)

Name Title Board Seat Contact Info
Michel Corbarieu Chief Operating Officer, Co-President & Financial Director
Richard Fabre Ph.D Co-Founder, President & Medical Director
Jean-Pierre Majoral Ph.D Co-Founder, Scientific Director & Scientific expert - Chemistry
Jean-Marie François Co-Founder and Scientific director
Alain Léonard Co-Founder
To view Dendris’s complete executive team members history, request access »

Dendris Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Capitole Angels Angel Group Minority 000 0000 000000 0
Nubbo Accelerator/Incubator 000 0000 000000 0
To view Dendris’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »